ASHLEIGH GASPARAC: Open Payments
NPI 1912386418 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,004 in 41 payments from 11 companies in 2025. Trend: 2023 $321 · 2024 $421 · 2025 $2,004
Food & beverage: $2,004
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $637 |
| Vanda Pharmaceuticals Inc. | 3 | $314 |
| Neurocrine BioSciences, Inc. | 2 | $211 |
| Lilly USA, LLC | 2 | $132 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $121 |
| Noven Therapeutics, LLC | 1 | $120 |
| Collegium Pharmaceutical, Inc. | 1 | $120 |
| Alkermes, Inc. | 1 | $116 |
| Axsome Therapeutics, Inc. | 1 | $116 |
| Teva Pharmaceuticals USA, Inc. | 1 | $101 |
Products named: VRAYLAR, FANAPT, INGREZZA, ZEPBOUND, CAPLYTA, Xelstrym, Jornay PM, LYBALVI.
Industry payments across KY — which companies pay providers there.
